• Abiraterone Acetate: Applied CYP17 Inhibitor Workflows in Pr

  2026-05-08

  Unlock the full translational power of Abiraterone acetate—an advanced CYP17 inhibitor—across patient-derived 3D models and CRPC assays. This practical guide details workflow enhancements, protocol specifics, and troubleshooting strategies that elevate experimental rigor and reproducibility.

• CDK7 Inhibitor Resistance: Role of Conserved Mutation D97N i

  2026-05-07

  This study uncovers how a conserved mutation (D97N) in CDK7 drives resistance to non-covalent CDK7 inhibitors in cancer cells, while retaining sensitivity to covalent inhibitors. The findings clarify critical aspects of drug resistance mechanisms and inform future design and application of transcription regulation inhibitors in cancer research.

• Okadaic acid (A4540): Practical Use as a Protein Phosphatase

  2026-05-07

  Okadaic acid is a nanomolar-range inhibitor of protein phosphatase 1 and 2A, enabling precise interrogation of phosphorylation-dependent signaling in cell biology and biochemical workflows. It is best used where robust, selective inhibition of serine/threonine phosphatases is required, such as apoptosis induction and signal transduction studies. Okadaic acid should not be substituted in workflows where off-target effects or extreme potency may compromise assay specificity.

• Resveratrol’s Hormetic Rescue of Radiation-Induced Endotheli

  2026-05-06

  This study establishes an in vitro endothelial model to quantify radiation-induced vascular injuries and demonstrates that resveratrol exerts a dose-dependent, hormetic rescue effect on endothelial DNA and tube formation. These findings enable robust screening of radioprotective compounds and offer mechanistic insights for advancing vascular protection strategies after ionizing radiation exposure.

• Optimizing Cell Assays with PR-619: Practical Guidance for B

  2026-05-06

  This article provides scenario-driven, data-backed guidance for using PR-619 (SKU A8212), a broad-spectrum deubiquitylating enzymes inhibitor, in cell viability, proliferation, and cytotoxicity assays. Drawing on validated protocols and comparative analysis, we address common lab challenges and demonstrate when and why PR-619 offers reproducibility and workflow advantages in biomedical research.

• MLN4924 HCl Salt: NEDD8-Activating Enzyme Inhibition in Canc

  2026-05-05

  MLN4924 HCl salt is a potent and selective small molecule NEDD8-activating enzyme inhibitor. It enables precise disruption of the neddylation pathway, impacting cullin-RING ligase activity and downstream protein degradation critical to cancer biology. This article details its mechanism, benchmarks, and evidence-based protocols for rigorous research applications.

• Topotecan HCl in Cancer Research: Quantitative Assay Design

  2026-05-05

  Explore the scientific depth behind Topotecan HCl, a potent topoisomerase 1 inhibitor, and learn how modern assay metrics and practical protocols can optimize its use in advanced cancer research models.

• PR-619: Precision Deubiquitylating Enzymes Inhibitor in Work

  2026-05-04

  PR-619 empowers researchers to interrogate the ubiquitination pathway with unmatched breadth and consistency, delivering actionable insights in cancer biology and neurodegenerative disease models. This guide navigates applied workflows, optimization strategies, and recent scientific breakthroughs to help maximize your use of APExBIO’s PR-619.

• Gramine: A Precision Ferroptosis Inducer in Cancer Biology R

  2026-05-04

  Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) is a validated ferroptosis inducer that enables targeted interrogation of the CUL3–MTDH ubiquitination axis in triple-negative breast cancer. This article delivers protocol-driven insights, troubleshooting strategies, and advanced applications for leveraging high-purity Gramine from APExBIO in translational oncology research.

• Okadaic Acid (A4540): Practical Guidance for Phosphatase Inh

  2026-05-03

  Okadaic acid is a potent, marine-derived protein phosphatase 1 inhibitor used to dissect phosphorylation-dependent cellular mechanisms. It is best applied in apoptosis assays, cancer research, and signal transduction studies requiring selective PP1 and PP2A inhibition. This compound is not suitable where off-target phosphatase effects or solvent sensitivity are critical concerns.

• Origami Engineering of KR-12: Antimicrobial and Biofilm Solu

  2026-05-02

  This review explores origami-inspired engineering of KR-12, the smallest active fragment of LL-37, focusing on structural modifications that enhance antimicrobial, anti-biofilm, and immunomodulatory properties. The findings inform rational design of peptide therapeutics for resistant infections and biomaterial applications.

• U0126-EtOH: Selective MEK1/2 Inhibitor for MAPK/ERK Modulati

  2026-05-01

  U0126-EtOH is a highly selective MEK1/2 inhibitor used to dissect MAPK/ERK signaling in oxidative stress and inflammatory models. It demonstrates potent inhibition at nanomolar concentrations and is validated in both neuronal and in vivo asthma models. This article provides evidence-backed protocol guidance and clarifies common misconceptions.

• PYR-41: Inhibitor of Ubiquitin-Activating Enzyme E1 in NF-κB

  2026-05-01

  PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme E1, empowers researchers to dissect ubiquitin-proteasome system inhibition, NF-κB pathway modulation, and protein degradation workflows with robust, reproducible results. This article translates cutting-edge research into actionable experimental guidance, including protocol enhancements and troubleshooting strategies for apoptosis and inflammation assays.

• CB-5083 and p97 Inhibition: Deep Insights into Protein Homeo

  2026-04-30

  Explore the advanced mechanisms and unique research value of CB-5083, a potent p97 inhibitor, in protein homeostasis disruption and cancer apoptosis induction. This article offers a distinct, in-depth analysis informed by cutting-edge literature and practical assay guidance.

• Palonosetron Hydrochloride: Advances in Delayed CINV Managem

  2026-04-30

  This article examines recent advances in the management of chemotherapy- and radiotherapy-induced nausea and vomiting (CINV) with a focus on palonosetron hydrochloride. The reference study highlights the unique pharmacological properties and clinical efficacy of palonosetron, particularly for delayed CINV, and discusses its integration into clinical guidelines.

8554 records 16/571 page Previous Next First page 上5页 1617181920 下5页 Last page